Currently, only few biomarkers are available to predict treatment effectiveness in gastric cancer’s patients including the level of expression of human epidermal growth factor receptor 2 (HER2) for trastuzumab and the programmed death-ligand 1 (PD-L1) for pembrolizumab (15, 16), the last one allowed as a second line therapy for metastatic disease. This evidence concerns the gene ERBB2 and gastric cancer.